Anti Inflammatory News and Research RSS Feed - Anti Inflammatory News and Research

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration approved a Supplemental New Drug Application (sNDA) for Eliquis (apixaban) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. [More]

Molecular substance that occurs naturally in humans reduces brain damage after acute stroke

A molecular substance that occurs naturally in humans and rats was found to "substantially reduce" brain damage after an acute stroke and contribute to a better recovery, according to a newly released animal study by researchers at Henry Ford Hospital. [More]
Statins combined with conventional blood clot prevention therapies, reduce VTE risk by 48%

Statins combined with conventional blood clot prevention therapies, reduce VTE risk by 48%

Statins have long been known to lower cholesterol and, more recently, to decrease the risk of deep vein thrombosis (blood clots) in healthy, non-surgical patients. [More]
Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma, Inc. today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. [More]
Findings provide new target for development of novel therapies to manage chronic pain

Findings provide new target for development of novel therapies to manage chronic pain

Scientists have shown for the first time that the abnormalities in the way the brain experiences pain may be to blame for the chronic pain suffered by osteoarthritis patients. [More]
Research to identify exact mechanisms behind preterm birth and fetal brain injury

Research to identify exact mechanisms behind preterm birth and fetal brain injury

An inflammatory protein that triggers a pregnant mouse's immune response to an infection or other disease appears to cause brain injury in her fetus, but not the premature birth that was long believed to be linked with such neurologic damage in both rodents and humans, new Johns Hopkins-led research suggests. [More]
Kamada initiates Phase 2/3 clinical trial of Glassia to treat pediatric patients with T1D

Kamada initiates Phase 2/3 clinical trial of Glassia to treat pediatric patients with T1D

Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the initiation of a Phase 2/3 clinical trial of Glassia®, the Company's proprietary human Alpha-1 Antitrypsin (AAT), to treat newly diagnosed pediatric patients with type 1 diabetes (T1D). [More]

POZEN reports total revenue of $4.7 million for fourth quarter 2013

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the fourth quarter and year ended December 31, 2013. [More]

Drug that blocks LTA4 hydrolase enzyme plays key role in body's inflammatory response

There have been great expectations regarding the production of a drug to block the enzyme LTA4 hydrolase, which plays a key role in the body's inflammatory response. [More]
Scientists map key elements of immune overreaction triggered by influenza virus infection

Scientists map key elements of immune overreaction triggered by influenza virus infection

Scientists at The Scripps Research Institute (TSRI) have mapped key elements of a severe immune overreaction—a "cytokine storm"—that can both sicken and kill patients who are infected with certain strains of flu virus. [More]
Scientists discover new protein that is involved in cancer, inflammation in lung tissue

Scientists discover new protein that is involved in cancer, inflammation in lung tissue

Scientists from The University of Manchester - part of the Manchester Cancer Research Centre (MCRC) - have discovered a new protein that is involved in cancer and inflammation in lung tissue. [More]
LA BioMed researchers awarded NIH grant to pursue new approaches for treating MRSA

LA BioMed researchers awarded NIH grant to pursue new approaches for treating MRSA

With antibiotic resistant infections on the rise and a scarce pipeline of novel drugs to combat them, researchers at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center are pursuing entirely new approaches to meet the challenge of drug-resistant infections by taming microbes rather than killing them. [More]
Anika Therapeutics receives marketing approval from FDA for MONOVISC injection

Anika Therapeutics receives marketing approval from FDA for MONOVISC injection

Anika Therapeutics, Inc. today announced it has received marketing approval for MONOVISC from the U.S. Food and Drug Administration. MONOVISC is a single injection supplement to synovial fluid of the osteoarthritic joint, used to treat pain and improve joint mobility in patients suffering from osteoarthritis (OA) of the knee. [More]
Santalis Pharmaceuticals partners with TFS for marketing of OTC dermatology products

Santalis Pharmaceuticals partners with TFS for marketing of OTC dermatology products

Santalis Pharmaceuticals Inc., a joint venture with TFS Corporation Ltd., of Australia (ASX: TFC) is pleased to report the execution of an exclusive license agreement with a global pharmaceutical company for the marketing of a number of over-the-counter (OTC) dermatology products containing TFS' sustainably cultivated, pharmaceutical-grade East Indian Sandalwood Oil (EISO). [More]
New way to potentially block chronic pain affecting osteoarthritis sufferers

New way to potentially block chronic pain affecting osteoarthritis sufferers

Researchers from the Arthritis Research UK Pain Centre at The University of Nottingham have discovered a new way to potentially block the chronic and often debilitating pain affecting osteoarthritis sufferers. [More]
FDA approves Iroko Pharmaceuticals’ TIVORBEX capsules

FDA approves Iroko Pharmaceuticals’ TIVORBEX capsules

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved TIVORBEX™ (indomethacin) capsules, a nonsteroidal anti-inflammatory drug (NSAID), at 20 mg and 40 mg doses for the treatment of mild to moderate acute pain in adults. [More]
FDA approves sNDA to include radiographic data updating label of Pfizer XELJANZ for treatment of RA

FDA approves sNDA to include radiographic data updating label of Pfizer XELJANZ for treatment of RA

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) to update the current label of XELJANZ® (tofacitinib citrate) 5 mg tablets to include radiographic data from two Phase 3 studies, ORAL Scan (A3921044) and ORAL Start. [More]
New system delivers anti-inflammatory drugs to immune cells gone out of control

New system delivers anti-inflammatory drugs to immune cells gone out of control

Researchers at the University of Illinois at Chicago have developed a system for precisely delivering anti-inflammatory drugs to immune cells gone out of control, while sparing their well-behaved counterparts. Their findings were published online Feb. 23 in Nature Nanotechnology. [More]

Ways to help manage chronic pain

Musculoskeletal pain of the bone, joint and muscles is one of the most common reasons for primary care visits in the United States. According to a literature review appearing in a recent issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS), chronic pain, or pain that persists beyond an expected period of healing, is estimated to affect 100 million Americans. [More]
High levels of stress hormone cortisol may contribute to risk aversion in traders

High levels of stress hormone cortisol may contribute to risk aversion in traders

High levels of the stress hormone cortisol may contribute to the risk aversion and 'irrational pessimism' found among bankers and fund managers during financial crises, according to a new study. [More]